Hammerhead ribozyme

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Hammerhead Ribozyme
Hammerhead ribozyme ribbons.png
Stylized rendering of the full-length
hammerhead ribozyme RNA molecule
Scientific classification
Species: Catalytic RNA

The hammerhead ribozyme is a RNA module that catalyzes reversible cleavage and joining reactions at a specific site within an RNA molecule. It serves as a model system for research on the structure and properties of RNA, and is used for targeted RNA cleavage experiments, some with proposed therapeutic applications. Named for the resemblance of early secondary structure diagrams to a hammerhead shark [1] hammerhead ribozymes RNAs were originally discovered in two classes of plant virus-like RNAs: satellite RNAs and viroids. They have subsequently been found to be widely dispersed within many forms of life.

The self-cleavage reactions, first reported in 1986,[2][3] are part of a rolling circle replication mechanism. The hammerhead sequence is sufficient for self-cleavage[4] and acts by forming a conserved three-dimensional tertiary structure.

Catalysis[edit]

In the natural state, a hammerhead RNA motif is a single strand of RNA, and although the cleavage takes place in the absence of enzymes, the hammerhead RNA itself is not a catalyst in its natural state, as it is consumed by the reaction and cannot catalyze multiple turnovers.

Trans-acting hammerhead constructs can be engineered such that they consist of two RNA strands. The strand that gets cleaved can be supplied in excess, and multiple turnover can be demonstrated and shown to obey Michaelis-Menten kinetics, typical of protein enzyme kinetics. Such constructs are typically employed for in vitro experiments, and the term "hammerhead RNA" has become in practice synonymous with the more frequently used "hammerhead ribozyme".

The minimal trans-acting hammerhead ribozyme sequence that is catalytically active consists of three base-paired stems flanking a central core of 15 conserved (mostly invariant) nucleotides, as shown. The conserved central bases, with few exceptions, are essential for ribozyme’s catalytic activity. Such hammerhead ribozyme constructs exhibit in vitro a turnover rate (kcat) of about 1 molecule/minute and a Km on the order of 10 nanomolar.

The hammerhead ribozyme is arguably the best-characterized ribozyme. Its small size, thoroughly-investigated cleavage chemistry, known crystal structure, and its biological relevance make the hammerhead ribozyme particularly well-suited for biochemical and biophysical investigations into the fundamental nature of RNA catalysis.

Hammerhead ribozymes may play an important role as therapeutic agents; as enzymes which tailor defined RNA sequences, as biosensors, and for applications in functional genomics and gene discovery.[5]

Species distribution[edit]

Hammerhead ribozyme HH9
Hammerhead ribozyme HH9.jpg
Predicted secondary structure and sequence conservation of the HH9 ribozyme found conserved from lizard to human genomes
Identifiers
Symbol HH9
Rfam RF02275
Other data
RNA type Gene; ribozyme
Domain(s) Eukaryota
SO 0000380

In 1986, the first hammerhead ribozymes were found in some RNA plant pathogens like viroids and viral satellites.[2][3] One year later, a hammerhead ribozyme was also reported in the satellite DNA of newt genomes.[6] New examples of this ribozyme were then found in the genomes of unrelated organisms like schistosomes,[7] cave crickets,[8] Arabidopsis thaliana plant[9] and a few mammals like rodents and platypus.[10] In 2010, it was found that the hammerhead ribozyme actually occurs widespread from bacterial to eukaryal genomes[11] including humans.[12] Similar reports confirmed and extended these observations,[13][14][15] unveiling the hammerhead ribozyme as a ubiquitous catalytic RNA in all life kingdoms.[16]

In eukaryotic genomes, many of the detected hammerhead ribozymes seem to be related to short interspersed retroelements (SINEs),[11] with the exception of a family of strikingly conserved hammerheads found in the genomes of all amniotes.[12] These hammerhead ribozymes (the so-called HH9 and HH10) occur in the introns of a few specific genes and point to a preserved biological role during pre-mRNA biosynthesis[17]

Chemistry of catalysis[edit]

The hammerhead ribozyme carries out a very simple chemical reaction that results in the breakage of the substrate strand of RNA, specifically at C17, the cleavage-site nucleotide. Although RNA cleavage is often referred to as hydrolysis, the mechanism employed does not in fact involve the addition of water. Rather, the cleavage reaction is simply an isomerization that consists of rearrangement of the linking phosphodiester bond. It is the same reaction, chemically, that occurs with random base-mediated RNA degradation, except that it is highly site-specific and the rate is accelerated 10,000-fold or more.

Cleavage by phosphodiester isomerization[edit]

In-line transition-state for the hammerhead ribozyme reaction. A general base (B) abstracts a proton from the 2'-O, and a general acid (A), supplies a proton to the 5'-O leaving group as negative charge accumulates. The reaction product is a 2',3'-cyclic phosphate. The bonds breaking (shown in red) and forming (dashed lines) must be in the axial positions and reside approximately 180° apart, as shown. Electron movements are represented by curly arrows.

The cleavage reaction is a phosphodiester isomerization reaction that is initiated by abstraction of the cleavage-site ribose 2’-hydroxyl proton from the 2’-oxygen, which then becomes the attacking nucleophile in an “in-line” or SN2(P)-like reaction, although it is not known whether this proton is removed prior to or during the chemical step of the hammerhead cleavage reaction. (The cleavage reaction is technically not bimolecular, but behaves in the same way a genuine SN2(P) reaction does; it undergoes inversion of configuration subsequent to forming an associative transition-state consisting of a pentacoordinated oxyphosphrane.) The attacking and leaving group oxygens will both occupy the two axial positions in the trigonal bipyramidal transition-state structure as is required for an SN2-like reaction mechanism.

The 5’-product, as a result of this cleavage reaction mechanism, possesses a 2’,3’-cyclic phosphate terminus, and the 3’-product possesses a 5’-OH terminus, as with nonezymatic alkaline cleavage of RNA. The reaction is therefore reversible, as the scissile phosphate remains a phosphodiester, and may thus act as a substrate for hammerhead RNA-mediated ligation without a requirement for ATP or a similar exogenous energy source.[18] The hammerhead ribozyme-catalyzed reaction, unlike the formally identical non-enzymatic alkaline cleavage of RNA, is a highly sequence-specific cleavage reaction with a typical turnover rate of approximately 1 molecule of substrate per molecule of enzyme per minute at pH 7.5 in 10 mM Mg2+ (so-called “standard reaction conditions” for the minimal hammerhead RNA sequence), depending upon the sequence of the particular hammerhead ribozyme construct measured. This represents an approximately 10,000-fold rate enhancement over the nonezymatic cleavage of RNA.

Requirement for divalent metal ions[edit]

All ribozymes were originally thought to be metallo-enzymes, in the sense that they were assumed to require the presence of divalent cations, such as Mg2+, for both folding and catalysis. It was presumed that hexahydrated magnesium ions, which exist in equilibrium with magnesium hydroxide, could play the roles of general acid and general base, in a way analogous to those played by two histidines in RNase A. An additional role for divalent metal ions has also been proposed in the form of electrostatic stabilization of the transition-state.

Not a metallo-enzyme[edit]

In 1998 it was discovered[19] that the hammerhead ribozyme, as well as the VS ribozyme and hairpin ribozyme, do not require the presence of metal ions for catalysis, provided a sufficiently high concentration of monovalent cation is present to permit the RNA to fold. This discovery suggested that the RNA itself, rather than serving as an inert, passive scaffold for the binding of chemically active divalent metal ions, is instead itself intimately involved in the chemistry of catalysis. The latest structural results, described below, indeed confirm that two invariant nucleotides, G12 and G8, are positioned consistent with roles as the general base and general acid in the hammerhead cleavage reaction.

Strictly speaking, therefore, the hammerhead ribozyme cannot be a metallo-enzyme.

Primary and secondary structure[edit]

Secondary structures and sequences of the minimal (A) and full-length (B) hammerhead ribozymes. Conserved and invariant nucleotides are shown explicitly. Watson-Crick base-paired helical stems are represented as ladder-like drawings. The red arrow depicts the cleavage site, 3' to C17, on each construct.

Minimal ribozyme[edit]

The minimal hammerhead sequence that is required for the self-cleavage reaction includes approximately 13 conserved or invariant "core" nucleotides, most of which are not involved in forming canonical Watson-Crick base-pairs. The core region is flanked by Stems I, II and III, which are in general made of canonical Watson-Crick base-pairs but are otherwise not constrained with respect to sequence. The catalytic turnover rate of minimal hammerhead ribozymes is ~ 1/min (a range of 0.1/min to 10/min is commonly observed, depending upon the nonconserved sequences and the lengths of the three helical stems) under standard reaction conditions of high Mg2+ (~10 mM), pH 7.5 and 25°C. Much of the experimental work carried out on hammerhead ribozymes has used a minimal construct.

Type I, type II and type III hammerhead RNA[edit]

Hammerhead ribozyme (type I)
RF00163.jpg
Predicted secondary structure and sequence conservation of Hammerhead_1
Identifiers
Symbol Hammerhead_1
Rfam RF00163
Other data
RNA type Gene; ribozyme
Domain(s) Viroids; Eukaryota
SO 0000380
Hammerhead ribozyme (type III)
RF00008.jpg
Predicted secondary structure and sequence conservation of Hammerhead ribozyme (type III)
Identifiers
Symbol Hammerhead_3
Rfam RF00008
Other data
RNA type Gene; ribozyme
Domain(s) Viroids; Eukaryota
SO 0000380

Structurally the hammerhead ribozyme is composed of three base paired helices, separated by short linkers of conserved sequences. These helices are called I, II and III. Hammerhead ribozymes can be classified into three types based on which helix the 5' and 3' ends are found in. If the 5' and 3' ends of the sequence contribute to stem I then it is a type I hammerhead ribozyme, to stem II is a type II and to stem III then it is a type III hammerhead ribozyme. Of the three possible topological types, type I can be found in the genomes of prokaryotes, eukaryotes and RNA plant pathogens, whereas type II have been only described in prokaryotes[14][15] and type III are mostly found in plants, plant pathogens and prokaryotes.[16][17]

Full-length ribozyme[edit]

The full-length hammerhead ribozyme consists of additional sequence elements in stems I and II that permit additional tertiary contacts to form. The tertiary interactions stabilize the active conformation of the ribozyme, resulting in cleavage rates up to 1000-fold greater than those for corresponding minimal hammerhead sequences.[20][21]

Tertiary structure[edit]

Minimal[edit]

The crystal structure of a minimal hammerhead ribozyme

The minimal hammerhead ribozyme has been exhaustively studied by biochemists and enzymologists as well as by X-ray crystallographers, NMR spectroscopists, and other practitioners of biophysical techniques. The first detailed three-dimensional structural information for a hammerhead ribozyme appeared in 1994 in the form of an X-ray crystal structure of a hammerhead ribozyme bound to a DNA substrate analogue, published in Nature by Pley, Flaherty and McKay.[22] Subsequently, an all-RNA minimal hammerhead ribozyme structure was published by Scott, Finch and Klug in Cell in early 1995.[23]

The minimal hammerhead ribozyme is composed of three base paired helices, separated by short linkers of conserved sequence as shown in the crystal structure.[23] These helices are called I, II and III. The conserved uridine-turn links helix I to helix II and usually contains the sequence CUGA. Helix II and III are linked by a sequence GAAA. The cleavage reaction occurs between helix III and I, and is usually a C.

The structure of a full length ribozyme shows that there are extensive interactions between the loop of stem II and stem I.[24]

Structure-function[edit]

Despite the observations of hammerhead ribozyme catalysis in a crystal of the minimal hammerhead sequence in which the crystal lattice packing contacts by necessity confined the global positions of the distal termini of all three flanking helical stems, many biochemical experiments designed to probe transition-state interactions and the chemistry of catalysis appeared to be irreconcilable with the crystal structures.

For example, the invariant core residues G5, G8, G12 and C3 in the minimal hammerhead ribozyme were each observed to be so fragile that changing even a single exocyclic functional group on any one of these nucleotides results in a dramatic reduction or abolition of catalytic activity, yet few of these appeared to form hydrogen bonds involving the Watson-Crick faces of these nucleotide bases in any of the minimal hammerhead structures, apart from a G-5 interaction in the product structure.

A particularly striking and only recently observed example consisted of G8 and G12, which were identified as possible participants in acid/base catalysis. Once it was demonstrated that the hammerhead RNA does not require divalent metal ions for catalysis, it gradually became apparent that the RNA itself, rather than passively bound divalent metal ions, must play a direct chemical role in any acid-base chemistry in the hammerhead ribozyme active site. It was however completely unclear how G12 and G8 could accomplish this, given the original structures of the minimal hammerhead ribozyme.

Other concerns included an NOE between U4 and U7 of the cleaved hammerhead ribozyme that had also been observed during NMR characterization, which suggested that these nucleotide bases must approach one another closer than about 6 Å, although close approach of U7 to U4 did not appear to be possible from the crystal structure. Finally, as previously discussed, the attacking nucleophile in the original structures, the 2’-OH of C17, was not in a position amenable to in-line attack upon the adjacent scissile phosphate.

Perhaps most worrisome were experiments that suggested the A-9 and scissile phosphates must come within about 4 Å of one another in the transition-state, based upon double phosphorothioate substitution and soft metal ion rescue experiments; the distance between these phosphates in the minimal hammerhead crystal structure was about 18 Å, with no clear mechanism for close approach if the Stem II and Stem I A-form helices were treated as rigid bodies. Taken together, these results appeared to suggest that a fairly large-scale conformational change must have take place in order to reach the transition-state within the minimal hammerhead ribozyme structure.

For these reasons, the two sets of experiments (biochemical vs. crystallographic) appeared not only to be at odds, but to be completely and hopelessly irreconcilable, generating a substantial amount of discord in the field. No compelling evidence for dismissing either set of experimental results was ever made successfully, although many claims to the contrary were made in favor of each.

Full-length[edit]

Three-dimensional structure of the full-length hammerhead ribozyme

In 2006 a 2.2 Å resolution crystal structure of the full-length hammerhead ribozyme was obtained. This new structure (shown on the right) appears to resolve the most worrisome of the previous discrepancies. In particular, C17 is now positioned for in-line attack, and the invariant residues C3, G5, G8 and G12 all appear involved in vital interactions relevant to catalysis. Moreover, the A9 and scissile phosphates are observed to be 4.3 Å apart, consistent with the idea that, when modified, these phosphates could bind a single thiophilic metal ion. The structure also reveals how two invariant residues, G-12 and G-8, are positioned within the active site consistent with their previously proposed role in acid/base catalysis. G12 is within hydrogen bonding distance to the 2’–O of C17, the nucleophile in the cleavage reaction, and the ribose of G8 hydrogen bonds to the leaving group 5’-O. (see below), while the nucleotide base of G8 forms a Watson-Crick pair with the invariant C3. This arrangement permits one to suggest that G12 is the general base in the cleavage reaction, and that G8 may function as the general acid, consistent with previous biochemical observations. G5 hydrogen bonds to the furanose oxygen of C17, helping to position it for in-line attack. U4 and U7, as a consequence of the base-pair formation between G8 and C3, are now positioned such that an NOE between their bases is easily explained.

The crystal structure of the full-length hammerhead ribozyme thus clearly addresses all of the major concerns that appeared irreconcilable with the previous crystal structures of the minimal hammerhead ribozyme.

Structure and catalysis[edit]

The active site of the full-length hammerhead ribozyme. G12 is positioned consistent with a role as a general base in the cleavage reaction, and the 2'-OH of G8 is positioned for acid catalysis. Potentially "active" hydrogen bonds are shown as orange dotted lines. The 2'-O of C17 is shown to be aligned for nucleophilic attack along the blue dotted line trajectory.

The tertiary interactions in the full-length hammerhead ribozyme stabilize what strongly appears to be the active conformation. The nucleophile, the 2'-oxygen of the cleavage-site nucleotide, C17, is aligned almost perfectly for an in-line attack (the SN2(P) reaction). G12 is positioned within hydrogen bonding distance of this nucleophile, and therefore would be able to abstract a proton from the 2'-oxygen if G12 itself becomes deprotonated. The 2'-OH of G8 forms a hydrogen bond to the 5'-leaving group oxygen, and therefore potentially may supply a proton as negative charge accumulates on the 5'-oxygen of the ribose of A1.1.

The most likely explanation is then that G12, in the deprotonated form, is the general base, and the ribose of G8 is the general acid. The apparent kinetic pKa of the hammerhead ribozyme is 8.5, whereas the pKa of guanosine is about 9.5. It is possible that the pKa of G12 is perturbed from 9.5 to 8.5 in the hammerhead catalytic core; this hypothesis is currently the subject of intense investigation.

Possible transition-state interactions as extrapolated from the crystal structure.

If the invariant G8 is changed to C8, hammerhead catalysis is abolished. However, a G8C + C3G double-mutant that maintains the G8-C3 base pair found in the full-length hammerhead restores most of the catalytic activity. The 2'-OH of G8 has also been observed to be essential for catalysis; replacement of G8 with deoxyG8 greatly reduces the rate of catalysis, suggesting the 2'-OH is indeed crucial to the catalytic mechanism.

The close approach of the A9 and scissile phosphates requires the presence of a high concentration of positive charge. This is probably the source of the observation that divalent metal ions are required at low ionic strength, but can be dispensed with at higher concentrations of monovalent cations.

The reaction thus likely involves abstraction of the 2'-proton from C17, followed by nucleophilic attack upon the adjacent phosphate. As the bond between the scissile phosphorus and the 5'-O leaving group begins to break, a proton is supplied from the ribose of G8, which then likely reprotonates at the expense of a water molecule observed to hydrogen bond to it in the crystal structure.


Therapeutic applications[edit]

Modified hammerhead ribozymes are being tested as therapeutic agents.[25] Synthetic RNAs containing sequences complementary to the mutant SOD1 mRNA and sequences necessary to form the hammerhead catalytic structure are being studied as a possible therapy for amyotrophic lateral sclerosis. Work is also underway to find out whether they could be used to engineer HIV-resistant lines of T-cells. Modified hammerhead ribozyme adenoviruses have been shown to be potent in treating cancer both in vitro and in vivo.[26]

The therapeutic use of trans-cleaving hammerhead ribozymes has been severely hampered by its low-level activity in vivo. The true catalytic potential of trans-cleaving hammerhead ribozymes may be recouped in vivo and therapeutic derivatives are likely to complement other nucleic acid hybridizing therapeutic strategies. Already there are hammerhead ribozymes which are close to clinical application.[5]

References[edit]

  1. ^ Forster AC, Symons RH (1987). "Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites". Cell 49 (2): 211–220. doi:10.1016/0092-8674(87)90562-9. PMID 2436805. 
  2. ^ a b Prody GA, Bakos JT, Buzayan JM, Schneider IR, Bruening G (1986). "Autolytic Processing of Dimeric Plant Virus Satellite RNA". Science 231 (4745): 1577–1580. doi:10.1126/science.231.4745.1577. PMID 17833317. 
  3. ^ a b Hutchins CJ, Rathjen PD, Forster AC, Symons RH (1986). "Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid". Nucleic Acids Res. 14 (9): 3627–3640. doi:10.1093/nar/14.9.3627. PMC 339804. PMID 3714492. 
  4. ^ Forster AC, Symons RH. (1987). "Self-cleavage of virusoid RNA is performed by the proposed 55-nucleotide active site". Cell 50 (1): 9–16. doi:10.1016/0092-8674(87)90657-X. PMID 3594567. 
  5. ^ a b Hean J and Weinberg MS (2008). "The Hammerhead Ribozyme Revisited: New Biological Insights for the Development of Therapeutic Agents and for Reverse Genomics Applications". RNA and the Regulation of Gene Expression: A Hidden Layer of Complexity. Caister Academic Press. ISBN 978-1-904455-25-7. 
  6. ^ Epstein LM, Gall JG (1987). "Self-cleaving transcripts of satellite DNA from the newt". Cell 48 (3): 535–543. doi:10.1016/0092-8674(87)90204-2. PMID 2433049. 
  7. ^ Ferbeyre G, Smith JM, Cedergren R. (1998). "Schistosome satellite DNA encodes active hammerhead ribozymes". Mol. Cell. Biol. 18 (7): 3880–3888. PMC 108972. PMID 9632772. 
  8. ^ Rojas AA, Vazquez-Tello A, Ferbeyre G, Venanzetti F, Bachmann L, Paquin B, Sbordoni V, Cedergren R. (2000). "Hammerhead-mediated processing of satellite pDo500 family transcripts from Dolichopoda cave crickets". Nucleic Acids Res 28 (20): 4037–4043. doi:10.1093/nar/28.20.4037. PMC 110794. PMID 11024185. 
  9. ^ Przybilski R, Gräf S, Lescoute A, Nellen W, Westhof E, Steger G, Hammann C. (2005). "Functional hammerhead ribozymes naturally encoded in the genome of Arabidopsis thaliana". Plant Cell 17 (7): 1877–1885. doi:10.1105/tpc.105.032730. PMC 1167538. PMID 15937227. 
  10. ^ Martick M, Horan LH, Noller HF, Scott WG. (2008). "A discontinuous hammerhead ribozyme embedded in a mammalian messenger RNA". Nature 454 (7206): 899–902. doi:10.1038/nature07117. PMC 2612532. PMID 18615019. 
  11. ^ a b De la Peña M, García-Robles I. (2010). "Ubiquitous presence of the hammerhead ribozyme motif along the tree of life". RNA 16 (10): 1943–1950. doi:10.1261/rna.2130310. PMC 2941103. PMID 20705646. 
  12. ^ a b De la Peña M, García-Robles I. (2010). "Intronic hammerhead ribozymes are ultraconserved in the human genome". EMBO Rep 11 (9): 711–716. doi:10.1038/embor.2010.100. PMC 2933863. PMID 20651741. 
  13. ^ Seehafer C, Kalweit A, Steger G, Gräf S, Hammann C. (2011). "From alpaca to zebrafish: hammerhead ribozymes wherever you look". RNA 17 (1): 21–26. doi:10.1261/rna.2429911. PMC 3004062. PMID 21081661. 
  14. ^ a b Jimenez RM, Delwart E, Lupták A. (2011). "Structure-based search reveals hammerhead ribozymes in the human microbiome". J Biol Chem 286 (10): 7737–7743. doi:10.1074/jbc.C110.209288. PMC 3048661. PMID 21257745. 
  15. ^ a b Perreault J, Weinberg Z, Roth A, Popescu O, Chartrand P, Ferbeyre G, Breaker R.R. (2011). "Identification of Hammerhead Ribozymes in All Domains of Life Reveals Novel Structural Variations". In Wasserman, Wyeth W. PLoS Computational Biology 7 (5): e1002031. doi:10.1371/journal.pcbi.1002031. PMC 3088659. PMID 21573207. 
  16. ^ a b Hammann C, Luptak A, Perreault J, de la Peña M. (2012). "The ubiquitous hammerhead ribozyme". RNA 18 (5): 871–885. doi:10.1261/rna.031401.111. PMC 3334697. PMID 22454536. 
  17. ^ a b García-Robles I, Sánchez-Navarro J, de la Peña M. (2012). "Intronic hammerhead ribozymes in mRNA biogenesis". Biol Chem 393 (11): 1317–1326. doi:10.1515/hsz-2012-0223. PMID 23109545. 
  18. ^ Canny MD, Jucker FM, Pardi A. (2007). "Efficient ligation of the Schistosoma hammerhead ribozyme". Biochemistry 46 (12): 3826–3834. doi:10.1021/bi062077r. PMC 3203546. PMID 17319693. 
  19. ^ J.B. Murray, A.A. Seyhan, N.G. Walter, J.M. Burke and W.G. Scott (1998). "The hammerhead, hairpin and VS ribozymes are catalytically proficient in monovalent cations alone". Chem Biol 5 (10): 587–595. doi:10.1016/S1074-5521(98)90116-8. PMID 9818150. 
  20. ^ Khvorova A, Lescoute A, Westhof E, Jayasena SD. (2003). "Sequence elements outside the hammerhead ribozyme catalytic core enable intracellular activity". Nature Structural & Molecular Biology 10 (9): 708–712. doi:10.1038/nsb959. PMID 12881719. 
  21. ^ De la Peña M, Gago S., Flores R. (2003). "Peripheral regions of natural hammerhead ribozymes greatly increase their self-cleavage activity". EMBO J 22 (20): 5561–5570. doi:10.1093/emboj/cdg530. PMC 213784. PMID 14532128. 
  22. ^ Pley HW, Flaherty KM, McKay DB. (1994). "Three-dimensional structure of a hammerhead ribozyme". Nature 372 (6501): 68–74. doi:10.1038/372068a0. PMID 7969422. 
  23. ^ a b Scott WG, Finch JT, Klug A. (1995). "The crystal structure of an all-RNA hammerhead ribozyme: a proposed mechanism for RNA catalytic cleavage". Cell 81 (7): 991–1002. doi:10.1016/S0092-8674(05)80004-2. PMID 7541315. 
  24. ^ Martick M, Scott WG (2006). "Tertiary contacts distant from the active site prime a ribozyme for catalysis". Cell 126 (2): 309–320. doi:10.1016/j.cell.2006.06.036. PMID 16859740. 
  25. ^ Citti L, Rainaldi G. (2005). "Synthetic hammerhead ribozymes as therapeutic tools to control disease genes". Current Gene Therapy 5 (1): 11–24. doi:10.2174/1566523052997541. PMID 15638708. 
  26. ^ Qi Fei,Hongyu Zhang, Lili Fu, Xinlan Dai, Baomei Gao, Min Ni, Chao Ge, Jinjun Li, Xia Ding, Yuwen Ke,Xuebiao Yao,Jingde Zhu (2008). "Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes". Acta Biochim Biophys Sin: 466–477. 

External links[edit]